Inactive Instrument

Radius Health, Inc.

Equities

RDUS

US7504692077

Biotechnology & Medical Research

Radius Health : to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021

October 20, 2021 at 03:00 pm EDT

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its third quarter financial results on Monday, November 8, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the results and provide a company update.

Conference Call Information:
Domestic Dial-In Number: 1 (855) 404-2458
International Dial-In Number: 1 (430) 775-1272
Conference ID: 9322858
Webcast Link: https://edge.media-server.com/mmc/p/945gpbaj

A replay of the conference call will be available on November 8 at 11:30 a.m. ET and a live audio webcast of the call will be archived on the Company's website for ninety days. To access the replay, dial (855) 859-2056 or (404) 537-3406 for International, using conference ID number 9322858. The live audio webcast of the call can be accessed from the Investors section of the Company’s website, https://ir.radiuspharm.com/events-and-presentations. The full text of the announcement and financial results will also be available on the Company’s website.

About Radius
Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. Radius’ lead product, TYMLOS^® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome.

Investor & Media Relations Contact:
Ethan Holdaway
Email: investor-relations@radiuspharm.com
Phone: (617) 583-2017

Source: Radius Health Inc.

2021 GlobeNewswire, Inc., source Press Releases

Latest news about Radius Health, Inc.

EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Radius Health, Inc for Binosto for the United States	23-09-19	CI
Radius Health, Inc. Announces the Appointment of Al Medwar as Senior Vice President and Corporate Development	23-07-27	CI
Radius Health, Inc. Appoints Erika Tooman as Senior Vice President/ General Counsel	23-04-06	CI
Theramex Enters into an Exclusive Licensing Agreement with Radius Health Inc, to Commercialise ELADYNOS in the European Economic Area, United Kingdom, Australia and Brazil	23-03-20	CI
Radius Health, Inc. announced that it has received funding from Webster Equity Partners, LLC	22-12-30	CI
Radius Health's Tymlos® (Abaloparatide) Receives U.S. FDA Approval as A Treatment to Increase Bone Density in Men with Osteoporosis At High Risk for Fracture	22-12-20	CI
Ambrx Biopharma Names Kate Hermans Interim CEO	22-08-16	MT
Radius Health, Inc. Announces Board Changes	22-08-15	CI
Radius Health, Inc. Enters into Credit Agreement	22-08-15	CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from NASDAQ Composite Index	22-08-15	CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from S&P TMI Index	22-08-15	CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from S&P Global BMI Index	22-08-15	CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from S&P Biotechnology Select Industry Index	22-08-15	CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from NASDAQ Biotechnology Index	22-08-10	CI
Patient Square Capital, LP and Gurnet Point Capital Limited completed the acquisition of Radius Health, Inc. from Repertoire Partners LP, Velan Capital Investment Management LP and others.	22-08-09	CI
Radius Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
Radius Health, Inc. and Teijin Pharma Limited Enter into an Amendment to License and Development Agreement	22-08-02	CI
Velan-Repertoire to Withdraw Director Nominations due to Pending Sale of Radius Health	22-07-11	CI
Radius Health Inc Issues an Investor Presentation to Shareholders	22-07-08	CI
Radius Health Solicits Proxies from Shareholders	22-07-07	CI
Radius Health Says First Patient Randomized in Trial of Prader-Willi Syndrome Symptoms	22-07-07	MT
Radius Health, Inc. Announces First Patient Randomized in the Rad011 Pivotal Trial for Prader-Willi Syndrome	22-07-07	CI
Radius Health, Inc Provides Information to the Shareholders	22-06-27	CI
Velan Capital Investment Comments on Proposed Sale of Radius Health to Gurnet Point Capital and Patient Square Capital	22-06-24	CI
SVB Securities Adjusts Radius Health's Price Target to $10 from $7, Keeps Market Perform Rating	22-06-24	MT

Chart Radius Health, Inc.

Duration

Period

More charts

Company Profile

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.39%	102B
REGENERON PHARMACEUTICALS, INC.	+2.61%	96.09B
ARGENX SE	-1.02%	22.05B
BIONTECH SE	-18.14%	20.81B
GENMAB A/S	-6.87%	19.06B
WUXI APPTEC CO., LTD.	-40.70%	16.05B
BEIGENE, LTD.	-26.89%	14.01B
NEUROCRINE BIOSCIENCES, INC.	+1.12%	13.38B
SAREPTA THERAPEUTICS, INC.	+22.25%	11.01B

Bio Therapeutic Drugs